-
Something wrong with this record ?
ROCK inhibitors as emerging therapeutic candidates for sarcomas
S. Micuda, D. Rösel, A. Ryska, J. Brábek,
Language English Country Netherlands
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Cell Adhesion drug effects MeSH
- Protease Inhibitors therapeutic use MeSH
- Protein Kinase Inhibitors therapeutic use MeSH
- rho-Associated Kinases antagonists & inhibitors metabolism MeSH
- Humans MeSH
- Cell Movement drug effects MeSH
- Sarcoma drug therapy MeSH
- Signal Transduction drug effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Sarcomas are malignant mesenchymal tumors of variable aggressiveness characterized by a substantial invasive and metastatic potential. In this review we discuss current results of pharmacological targeting of Rho/ROCK signaling in tumor cells, and the growing evidence supporting the hypothesis that Rho/ROCK dependent amoeboid mode of invasion could play a substantial role in metastatic potential of cells of malignant tumors, particularly of sarcomas. We attempt to cover pharmacological, biological and pathological aspects of the problematic in a multidisciplinary manner, from the views of molecular biology to medical practice. We are presenting evidence that blockade of Rho/ROCK pathway decreases amoeboid tumor cell invasion in vitro and substantially attenuates tumor growth and metastasis in vivo. While ROCK inhibitors have been used for a long time in treatment of cardiovascular diseases, the potential use of ROCK inhibitors to treat cancer metastasis has been considered only very recently. We propose that determination of the invasion mode that prevails in a particular sarcoma tumor, together with appropriate use of Rho/ROCK inhibitors could significantly improve the effectiveness of sarcoma tumor treatment in the future.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12025956
- 003
- CZ-PrNML
- 005
- 20121207092825.0
- 007
- ta
- 008
- 120817s2010 ne f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.2174/156800910791054202 $2 doi
- 035 __
- $a (PubMed)20088801
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Micuda, Stanislav $u Department of Pharmacology, Charles University Faculty of Medicine, Hradec Kralove, Czech Republic.
- 245 10
- $a ROCK inhibitors as emerging therapeutic candidates for sarcomas / $c S. Micuda, D. Rösel, A. Ryska, J. Brábek,
- 520 9_
- $a Sarcomas are malignant mesenchymal tumors of variable aggressiveness characterized by a substantial invasive and metastatic potential. In this review we discuss current results of pharmacological targeting of Rho/ROCK signaling in tumor cells, and the growing evidence supporting the hypothesis that Rho/ROCK dependent amoeboid mode of invasion could play a substantial role in metastatic potential of cells of malignant tumors, particularly of sarcomas. We attempt to cover pharmacological, biological and pathological aspects of the problematic in a multidisciplinary manner, from the views of molecular biology to medical practice. We are presenting evidence that blockade of Rho/ROCK pathway decreases amoeboid tumor cell invasion in vitro and substantially attenuates tumor growth and metastasis in vivo. While ROCK inhibitors have been used for a long time in treatment of cardiovascular diseases, the potential use of ROCK inhibitors to treat cancer metastasis has been considered only very recently. We propose that determination of the invasion mode that prevails in a particular sarcoma tumor, together with appropriate use of Rho/ROCK inhibitors could significantly improve the effectiveness of sarcoma tumor treatment in the future.
- 650 _2
- $a buněčná adheze $x účinky léků $7 D002448
- 650 _2
- $a pohyb buněk $x účinky léků $7 D002465
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a inhibitory proteas $x terapeutické užití $7 D011480
- 650 _2
- $a inhibitory proteinkinas $x terapeutické užití $7 D047428
- 650 _2
- $a sarkom $x farmakoterapie $7 D012509
- 650 _2
- $a signální transdukce $x účinky léků $7 D015398
- 650 _2
- $a kinázy asociované s rho $x antagonisté a inhibitory $x metabolismus $7 D054460
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Rösel, Daniel
- 700 1_
- $a Ryska, Ales
- 700 1_
- $a Brábek, Jan
- 773 0_
- $w MED00007909 $t Current cancer drug targets $x 1873-5576 $g Roč. 10, č. 2 (2010), s. 127-34
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20088801 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20121207092900 $b ABA008
- 999 __
- $a ok $b bmc $g 947998 $s 783302
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 10 $c 2 $d 127-34 $i 1873-5576 $m Current cancer drug targets $n Curr Cancer Drug Targets $x MED00007909
- LZP __
- $a Pubmed-20120817/10/03
